NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM, EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B
* VAT and and shipping costs not included. Errors and price changes excepted